Risk-benefit of tirzepatide, semaglutide, and bariatric surgery in obesity

Lucca Lorenzo Déo Malaquini; Lucas Franklin   Rocha de Souza; Leonardo   Ebani Parada; Julia   Gonçalves Grasso; Natália Abou   Hala Nunes

doi:10.59471/ijhsc2025277

Authors

Lucca Lorenzo Déo Malaquini Universidad de de Taubaté – UNITAU. Brazil Author https://orcid.org/0009-0003-9690-5209
Lucas Franklin Rocha de Souza Universidad de Taubaté – UNITAU. Brazil. Author https://orcid.org/0009-0009-9887-5887
Leonardo Ebani Parada Universidad de Taubaté – UNITAU. Brazil Author https://orcid.org/0009-0002-5079-7268
Julia Gonçalves Grasso Universidad de Taubaté – UNITAU. Brazil Author https://orcid.org/0009-0003-5879-5379
Natália Abou Hala Nunes Universidad de Taubaté – UNITAU. Brazil Author https://orcid.org/0000-0003-4122-7562

DOI:

https://doi.org/10.59471/ijhsc2025277

Keywords:

Obesity, Tirzepatide, Bariatric surgery

Abstract

Objective: Identify the best method for treating overweight/obesity in adults by analyzing their characteristics, benefits, and side effects. Methods: This is an integrative review composed of the following stages: 1. formulation of the guiding question; 2. literature search; 3. data collection; 4. critical analysis of the articles; 5. discussion of the results; 6. presentation of the integrative review. The databases Pubmed, BIREME, and SCIELO were consulted. Inclusion criteria were articles available in full, published in the last 5 years (2020 - 2024 ), in English or Portuguese. Articles were transferred to Rayyan software, where duplicates and those not meeting the inclusion criteria, such as studies on children and review articles, were excluded. Results: The results showed that Tirzepatide, compared to Semaglutide, was superior in reducing BMI, abdominal circumference, and weight percentage. Adverse effects occurred in both studies, mainly gastrointestinal, with no preference for either drug to reduce these effects. Comparison between Semaglutide or Tirzepatide versus Bariatric Surgery was not possible, as no studies addressing this comparison were found. Conclusions: Future research comparing medicinal and surgical approaches for weight reduction in obese patients is necessary to determine the best treatment, considering both weight reduction and undesirable post-treatment effects. More research on weight regain after study completion is also needed

References

Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight. N Engl J Med. 2023;388(10):920-31.

Seijas-Amigo J, García-Luna PP, González-Rodríguez VM, Gómez-Candela C. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase. Obes Surg. 2023;33(3):721-9.

Kolotkin RL, Davidson LE, Meinert CL, Williams N. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial. Diabetes Obes Metab. 2023;25(2):341-8.

Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. N Engl J Med. 2022;386(13):1190-201.

Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Nat Med. 2022;28(5):896-904.

Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(3):589-98.

Figueiredo Y. Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission. Obes Surg. 2023;33(1):133-8.

Lautenbach A, Murad MH, Alahdab F, Oberg A. The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis. Obes Surg. 2022;32(3):647-54.

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Li Y, Collins S, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-16.

Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, et al. Effect of once-weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. Diabetes Care. 2022;45(8):1833-41.

Gallwitz B, Giorgino F, Khunti K, Lupiáñez-Cuenca C, Frías JP, Madsbad S, et al. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Diabetes Obes Metab. 2021;23(6):1439-45.

Rubino D, Abrahamson MJ, Davies M, Hesse D, Greenway FL, Karim S, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-25.

Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

Friedrichsen M, Altintas S, Pape A, Janczy A, Reitz T. The effect of semaglutide 2.4 mg once weekly on energy intake appetite control of eating and gastric emptying in adults with obesity. Obes Surg. 2020;30(6):2167-75.

Kosiborod MN, Leiter LA, Gregson J, Small DS, Johnson KW, Silverman MG, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Nat Med. 2022;28(6):1165-72.

Blundell JE, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. The role of tirzepatide, a dual GIP and GLP-1 receptor agonist, in the treatment of obesity and its comorbidities. Pharmacol Res. 2021;169:105664.

Singh G, Krauthamer M, Bjalme-Evans M. Comparative efficacy of GLP-1 receptor agonists in type 2 diabetes: a systematic review and network meta-analysis. Diabetes Ther. 2021;12(1):285-300.

Carel W. Le Roux. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Nat Med. 2022;28(5):896-904.

Kosiborod MN, Leiter LA, Gregson J, Small DS, Johnson KW, Silverman MG, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Nat Med. 2022;28(6):1165-72.

Lautenbach A, Murad MH, Alahdab F, Oberg A. The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis. Obes Surg. 2022;32(3):647-54.